These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3369446)

  • 1. A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers.
    Jorde LB; Lathrop GM
    Am J Hum Genet; 1988 Jun; 42(6):808-15. PubMed ID: 3369446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The seasonal variation of births of offspring from couples heterozygous for cystic fibrosis.
    Brackenridge CJ
    Ann Hum Genet; 1978 Oct; 42(2):197-201. PubMed ID: 727711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex ratio and heterozygote advantage in cystic fibrosis families.
    Pritchard DJ; Hickman GR; Nelson R
    Arch Dis Child; 1983 Apr; 58(4):290-3. PubMed ID: 6847232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions.
    Miller AC; Comellas AP; Hornick DB; Stoltz DA; Cavanaugh JE; Gerke AK; Welsh MJ; Zabner J; Polgreen PM
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1621-1627. PubMed ID: 31882447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why is the cystic fibrosis gene so frequent?
    Romeo G; Devoto M; Galietta LJ
    Hum Genet; 1989 Dec; 84(1):1-5. PubMed ID: 2691388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothesis: a selective advantage for cystic fibrosis heterozygotes.
    Meindl RS
    Am J Phys Anthropol; 1987 Sep; 74(1):39-45. PubMed ID: 3318490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expected effects of mass screening policies on the frequency of cystic fibrosis homozygotes.
    Bertorelle G; Barbujani G
    Hum Genet; 1997 Oct; 100(5-6):666-8. PubMed ID: 9341889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between carrier screening and incidence of cystic fibrosis.
    Castellani C; Picci L; Tamanini A; Girardi P; Rizzotti P; Assael BM
    JAMA; 2009 Dec; 302(23):2573-9. PubMed ID: 20009057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of delta F508 cystic fibrosis carriers in The Netherlands: logistic regression on sex, age, region of residence and number of offspring.
    de Vries HG; Collée JM; de Walle HE; van Veldhuizen MH; Smit Sibinga CT; Scheffer H; ten Kate LP
    Hum Genet; 1997 Jan; 99(1):74-9. PubMed ID: 9003498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis.
    Sereth H; Shoshani T; Bashan N; Kerem BS
    Hum Genet; 1993 Oct; 92(3):289-95. PubMed ID: 7691712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies.
    Brock DJ; Gilfillan A; Holloway S
    Clin Genet; 1998 Jan; 53(1):47-9. PubMed ID: 9550361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female cystic fibrosis mutation carriers and assisted reproductive technology: does carrier status affect reproductive outcomes?
    VanWort TA; Lee JA; Karvir H; Whitehouse MC; Beim PY; Copperman AB
    Fertil Steril; 2014 Nov; 102(5):1324-30. PubMed ID: 25217870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 10-year large-scale cystic fibrosis carrier screening in the Italian population.
    Picci L; Cameran M; Marangon O; Marzenta D; Ferrari S; Frigo AC; Scarpa M
    J Cyst Fibros; 2010 Jan; 9(1):29-35. PubMed ID: 19897426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population.
    Abeliovich D; Lavon IP; Lerer I; Cohen T; Springer C; Avital A; Cutting GR
    Am J Hum Genet; 1992 Nov; 51(5):951-6. PubMed ID: 1384328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis.
    Schroeder SA; Gaughan DM; Swift M
    Nat Med; 1995 Jul; 1(7):703-5. PubMed ID: 7585155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Genetics Society of Australasia position statement: population-based carrier screening for cystic fibrosis.
    Delatycki MB; Burke J; Christie L; Collins F; Gabbett M; George P; Haan E; Ioannou L; Martin N; McKenzie F; O'Leary P; Scoble-Williams N; Turner G; Massie J;
    Twin Res Hum Genet; 2014 Dec; 17(6):578-83. PubMed ID: 25431289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis.
    Nielsen AO; Qayum S; Bouchelouche PN; Laursen LC; Dahl R; Dahl M
    J Cyst Fibros; 2016 Sep; 15(5):563-7. PubMed ID: 27324553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis carrier frequencies in populations of African origin.
    Padoa C; Goldman A; Jenkins T; Ramsay M
    J Med Genet; 1999 Jan; 36(1):41-4. PubMed ID: 9950364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis in the Ohio Amish: gene frequency and founder effect.
    Klinger KW
    Hum Genet; 1983; 65(2):94-8. PubMed ID: 6654341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cystic fibrosis heterozygote--advantage in surviving cholera?
    Rodman DM; Zamudio S
    Med Hypotheses; 1991 Nov; 36(3):253-8. PubMed ID: 1724059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.